Most people with relapsing-remitting multiple sclerosis (the most common form) average about one flare-up every three to four years when untreated or on older therapies. In clinical data, the average annualized relapse rate during the first three years after diagnosis is around 0.27, meaning roughly one relapse for every three to four years of disease. But that number is a population average. Some people go years without a single flare, while others experience two or more in a single year, especially early in the disease.
What Counts as a Flare-Up
Not every bad day is a true relapse. Clinically, a flare-up is defined as the appearance of new neurological symptoms, or a clear worsening of existing ones, that lasts at least 24 hours and isn’t caused by a fever or infection. A typical relapse builds over 24 to 48 hours and reaches its worst point within several days. Symptoms might include new numbness, vision problems, difficulty walking, or unusual fatigue that clearly differs from your baseline.
To be considered a separate relapse from a previous one, the new episode generally needs to occur at least 30 days after the start of the last flare. Anything closer together is usually treated as part of the same event.
Pseudo-Flares Feel Real but Aren’t New Damage
A pseudo-relapse is a temporary worsening of MS symptoms triggered by something outside the disease itself, most commonly an infection, heat exposure, or physical exhaustion. Your old symptoms flare up, sometimes dramatically, but no new inflammation is happening in the brain or spinal cord. The giveaway is that symptoms improve once the trigger resolves: once a fever breaks, or you cool down, things return to baseline.
Research shows that infections of any type significantly increase the odds of a pseudo-relapse, with most occurring within the month surrounding the illness. These episodes can be alarming, but they don’t represent new disease activity. Telling the difference between a true relapse and a pseudo-relapse often requires a neurologist’s assessment and sometimes an MRI.
What Triggers a True Relapse
Flare-ups are driven by the immune system attacking the protective coating around nerve fibers, and several factors can tip the balance. Stressful life events carry a moderate but consistent link to increased relapse risk. Extreme stress, such as exposure to wartime conditions, has been associated with up to a threefold increase in relapse risk in some studies.
Low vitamin D levels also play a role. For every meaningful increase in blood vitamin D concentration, relapse risk drops by about 10%. While that’s not a dramatic shield on its own, it’s one of the few modifiable factors with solid data behind it. Interestingly, autumn appears to be slightly protective against relapses, though the effect is small and no other season shows a clear pattern in either direction.
How Pregnancy Affects Flare Frequency
Pregnancy itself tends to suppress MS activity. Relapse rates during pregnancy drop well below the pre-pregnancy baseline for most women. The vulnerable window is the postpartum period. In a large dataset of women on lower-efficacy treatments, about 7.6% experienced a relapse during pregnancy, but that jumped to 17.6% in the year after delivery. The annualized relapse rate roughly tripled from pregnancy to postpartum in that group.
Women on more potent therapies fared better. Those on certain high-efficacy treatments had postpartum relapse rates as low as 4 to 5%. The takeaway is that the postpartum spike is real but manageable, and the choice of treatment strategy around pregnancy significantly shapes that risk.
How Flare Frequency Changes Over Time
Relapses are most common in the early years after diagnosis. About 26% of people who experience a first neurological event (called clinically isolated syndrome) go on to have a second event within one year, which typically confirms an MS diagnosis. The first five to ten years of relapsing-remitting MS tend to carry the highest relapse rates.
Over time, many people transition to a phase called secondary progressive MS, where the pattern shifts. Flare-ups become less frequent or stop entirely, but disability accumulates more steadily through a slow, grinding progression rather than through distinct attacks. Inflammation in the brain and spinal cord doesn’t disappear in this phase, but it decreases with age and disease duration. Some people with secondary progressive MS still experience occasional relapses, but they are the exception rather than the rule.
What Reduces Flare Frequency
Disease-modifying therapies are the primary tool for spacing out relapses and reducing their severity. The newer, higher-efficacy options can cut annualized relapse rates by 50 to 70% compared to no treatment, and some of the most potent therapies push relapse rates close to zero for many patients. Starting treatment early, ideally after the first clinical event, is consistently linked to better long-term outcomes.
Beyond medication, the modifiable risk factors with the strongest evidence include maintaining adequate vitamin D levels, managing stress where possible, and promptly treating infections to reduce the chance of both true relapses and pseudo-relapses. Menopause, for what it’s worth, appears to be mildly protective against relapses, likely due to hormonal shifts that dampen certain immune responses.
The honest reality is that flare-up frequency varies enormously from person to person. Two people with the same diagnosis can have wildly different relapse patterns. Tracking your own symptoms carefully, recognizing what a true relapse feels like versus a pseudo-flare, and working with your neurologist to adjust treatment when the pattern changes are the most practical steps for staying ahead of the disease.